WGS GeneDx Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: WGS

Price (delayed)

$85.2

Market cap

$2.54B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.64

Enterprise value

$2.65B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 62
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 19
Highlights
The gross profit is up by 30% year-on-year and by 2.4% since the previous quarter
WGS's revenue is up by 25% year-on-year and by 2.7% since the previous quarter
WGS's debt is up by 46% year-on-year
GeneDx Holdings's EPS has decreased by 37% QoQ
Sector: Healthcare
Industry: Health Information Services
Website: https://www.genedx.com
Peers: NEOG NTRA MYGN

Key stats

What are the main financial stats of WGS

WGS stock price

How has the GeneDx Holdings stock price performed over time
Intraday
-6.17%
1 week
-12.54%
1 month
-2.14%
1 year
-29.86%
YTD
-34.49%
QTD
24.11%

Financial performance

How have GeneDx Holdings's revenue and profit performed over time
Revenue
$454.43M
Gross profit
$315.24M
Operating income
-$92.41M
Net income
-$106.36M
Gross margin
69.4%
Net margin
-23.4%
The operating income has contracted by 40% from the previous quarter
The net income fell by 37% QoQ
The operating margin has contracted by 36% from the previous quarter
WGS's net margin is down by 33% since the previous quarter

Price vs fundamentals

How does WGS's price correlate with its fundamentals

Growth

What is GeneDx Holdings's growth rate over time

Valuation

What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
10.36
P/S
11.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.83
GeneDx Holdings's EPS has decreased by 37% QoQ
The stock's P/B is 145% more than its 5-year quarterly average of 4.5 and 15% more than its last 4 quarters average of 9.6
The company's equity fell by 12% YoY and by 3.9% QoQ
The stock's P/S is 170% above its 5-year quarterly average of 4.4 and 60% above its last 4 quarters average of 7.4
WGS's revenue is up by 25% year-on-year and by 2.7% since the previous quarter

Efficiency

How efficient is GeneDx Holdings business performance
The ROE has decreased by 41% from the previous quarter
The ROA is down by 35% since the previous quarter
GeneDx Holdings's return on sales has decreased by 34% QoQ
The ROIC has contracted by 23% from the previous quarter

Dividends

What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WGS.

Financial health

How did GeneDx Holdings financials performed over time
WGS's total assets is 103% greater than its total liabilities
The total liabilities has grown by 27% YoY but it has contracted by 6% from the previous quarter
The current ratio has increased by 15% year-on-year and by 7% since the previous quarter
WGS's debt is 31% smaller than its equity
The debt to equity has surged by 68% year-on-year and by 4.5% since the previous quarter
WGS's debt is up by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.